翰思艾泰-B(03378)获批准于中华人民共和国开展注射用HX111临床试验

智通财经2025-12-23

智通财经APP讯，翰思艾泰-B(03378)发布公告，由本公司开发的创新药注射用HX111(HX111)已获中华人民共和国国家药品监督管理局批准于中华人民共和国境内开展临床试验。HX111为首创(FIC)OX40靶向抗体偶联药物(ADC)。临床前研究表明，OX40为肿瘤相关抗原(TAA)，于若干恶性肿瘤(包括部分淋巴瘤)中相较于正常组织呈过度表达，因而成为如HX111等ADC方式的合适靶点。此外，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2593418386?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-23 21:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593418386","market":"sh","top_or_hot":-1,"title":"翰思艾泰-B(03378)获批准于中华人民共和国开展注射用HX111临床试验","media":"智通财经","content":"<div>\n<p>智通财经APP讯，翰思艾泰-B(03378)发布公告，由本公司开发的创新药注射用HX111(HX111)已获中华人民共和国国家药品监督管理局批准于中华人民共和国境内开展临床试验。HX111为首创(FIC)OX40靶向抗体偶联药物(ADC)。临床前研究表明，OX40为肿瘤相关抗原(TAA)，于若干恶性肿瘤(包括部分淋巴瘤)中相较于正常组织呈过度表达，因而成为如HX111等ADC方式的合适靶点。此外，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1385147.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>翰思艾泰-B(03378)获批准于中华人民共和国开展注射用HX111临床试验</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n翰思艾泰-B(03378)获批准于中华人民共和国开展注射用HX111临床试验\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-23 21:12 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1385147.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，翰思艾泰-B(03378)发布公告，由本公司开发的创新药注射用HX111(HX111)已获中华人民共和国国家药品监督管理局批准于中华人民共和国境内开展临床试验。HX111为首创(FIC)OX40靶向抗体偶联药物(ADC)。临床前研究表明，OX40为肿瘤相关抗原(TAA)，于若干恶性肿瘤(包括部分淋巴瘤)中相较于正常组织呈过度表达，因而成为如HX111等ADC方式的合适靶点。此外，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1385147.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1385147.html","article_id":"2593418386","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593418386","pubTimestamp":1766495577,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，翰思艾泰-B 发布公告，由本公司开发的创新药注射用HX111已获中华人民共和国国家药品监督管理局批准于中华人民共和国境内开展临床试验。HX111为首创OX40靶向抗体偶联药物。临床前研究表明，OX40为肿瘤相关抗原，于若干恶性肿瘤中相较于正常组织呈过度表达，因而成为如HX111等ADC方式的合适靶点。HX111为本公司继HX009及HX044两项FIC双特异性抗体疗法后，推进至临床开发的第三个首创分子。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"03378":"翰思艾泰-B","BK1173":"海港与服务","BK1535":"港口运输股"},"translate_title":"Hans Aitai-B (03378) was approved to conduct clinical trials of HX111 for injection in the People's Republic of China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1.5},"content_text":"智通财经APP讯，翰思艾泰-B(03378)发布公告，由本公司开发的创新药注射用HX111(HX111)已获中华人民共和国国家药品监督管理局批准于中华人民共和国境内开展临床试验。HX111为首创(FIC)OX40靶向抗体偶联药物(ADC)。临床前研究表明，OX40为肿瘤相关抗原(TAA)，于若干恶性肿瘤(包括部分淋巴瘤)中相较于正常组织呈过度表达，因而成为如HX111等ADC方式的合适靶点。此外，OX40亦在肿瘤微环境 (TME)中的调节性T细胞(Treg)呈过度表达，而该等Treg已知可抑制抗肿瘤免疫。清除该等Treg代表癌症免疫疗法的一种新作用机制(MOA)，此效应可透过HX111 实现，具备潜在泛癌症应用前景。HX111为本公司继HX009及HX044两项FIC双特异性抗体(BsAb)疗法后，推进至临床开发的第三个首创分子。本公司将继续努力，透过临床开发带来更多新颖 FIC药物，并最终推向市场。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2593418386","isCrawlerRequest":true}